REG - Adv Medical Solutns. Montagu Pvt Eqty LLP - Response to Rule 2.8 Announcement

Advanced Medical SolutionsAnnouncement

24/04/2025 16:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250424:nRSX1121Ga&default-theme=true

RNS Number : 1121G  Advanced Medical Solutions Grp PLC  24 April 2025

FOR IMMEDIATE RELEASE

 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR
FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE
RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

 

 

24 April 2025

Advanced Medical Solutions Group plc

("AMS" or the "Company")

Response to Rule 2.8 announcement from Montagu Private Equity LLP ("Montagu")

The Board of AMS notes the announcement made earlier today by Montagu
confirming that it does not intend to make an offer for AMS. As a result,
Montagu is bound by the restrictions set out in Rule 2.8 of the City Code on
Takeovers and Mergers.

The Board of AMS is pleased with performance in the year to date and has
strong conviction in AMS's strategy which it believes will drive growth and
value creation for shareholders.

Enquiries:

 

 Advanced Medical Solutions Group plc              +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Head of Investor Relations

 Evercore Partners International LLP               +44 (0) 207 653 6000

 (Financial Adviser)
 Simon Elliott

 Julian Oakley

 Torera Oyewo

 Harrison George

 Investec Bank PLC                                 +44 (0) 207 597 5970

 (Financial Adviser, NOMAD and Corporate Broker)
 Gary Clarence

 David Anderson

 ICR Consilium

 (PR Adviser)
 Mary-Jane Elliott                                 +44 (0) 20 3709 5700

 Lucy Featherstone                                 AMS@icrhealthcare.com

 

About AMS

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand(®), RESORBA(®),
LiquiBandFix8(®), LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G(®). AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal(®) brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,500 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com/) .

Person responsible

The person responsible for arranging the release of this announcement on
behalf of AMS is Eddie Johnson, Chief Financial Officer.

 

Rule 26.1

In accordance with Rule 26.1 of the Code, a copy of this announcement will be
available on the Company's website at www.admedsol.com
(http://www.admedsol.com/) . The content of the website referred to in this
announcement is not incorporated into and does not form part of this
announcement.

Important Notice

Evercore Partners International LLP ("Evercore"), which is authorised and
regulated by the Financial

Conduct Authority ("FCA") in the United Kingdom, is acting exclusively as
financial adviser to AMS and no one else in connection with the matters
described in this announcement and will not be responsible to anyone other
than AMS for providing the protections afforded to clients of Evercore nor for
providing advice in connection with the matters referred to herein. Neither
Evercore nor any of its subsidiaries, branches or affiliates owes or accepts
any duty, liability or responsibility whatsoever (whether direct or indirect,
whether in contract, in tort, under statute or otherwise) to any person who is
not a client of Evercore in connection with this announcement, any statement
contained herein, any offer or otherwise. Apart from the responsibilities and
liabilities, if any, which may be imposed on Evercore by the Financial
Services and Markets Act 2000, or the regulatory regime established
thereunder, or under the regulatory regime of any jurisdiction where exclusion
of liability under the relevant regulatory regime would be illegal, void or
unenforceable, neither Evercore nor any of its affiliates accepts any
responsibility or liability whatsoever for the contents of this announcement,
and no representation, express or implied, is made by it, or purported to be
made on its behalf, in relation to the contents of this announcement,
including its accuracy, completeness or verification of any other statement
made or purported to be made by it, or on its behalf, in connection with AMS
or the matters described in this document. To the fullest extent permitted by
applicable law, Evercore and its affiliates accordingly disclaim all and any
responsibility or liability whether arising in tort, contract or otherwise
(save as referred to above) which they might otherwise have in respect of this
announcement, or any statement contained herein.

Investec Bank plc ("Investec") is authorised in the United Kingdom by the
Prudential Regulation Authority ("PRA") and regulated in the United Kingdom by
the FCA and the PRA. Investec is acting exclusively as financial adviser and
corporate broker to AMS and no one else in connection with the matters
described in this announcement and will not be responsible to anyone other
than AMS for providing the protections afforded to clients of Investec, nor
for providing advice in connection with the matters referred to herein.
Neither Investec nor any of its subsidiaries, branches or affiliates owes or
accepts any duty, liability or responsibility whatsoever (whether direct or
indirect, whether in contract, in tort, under statute or otherwise) to any
person who is not a client of Investec in connection with this announcement,
any statement contained herein, any offer or otherwise. Apart from the
responsibilities and liabilities, if any, which may be imposed on Investec by
the Financial Services and Markets Act 2000, or the regulatory regime
established thereunder, or under the regulatory regime of any jurisdiction
where exclusion of liability under the relevant regulatory regime would be
illegal, void or unenforceable, neither Investec nor any of its affiliates
accepts any responsibility or liability whatsoever for the contents of this
announcement, and no representation, express or implied, is made by it, or
purported to be made on its behalf, in relation to the contents of this
announcement, including its accuracy, completeness or verification of any
other statement made or purported to be made by it, or on its behalf, in
connection with AMS or the matters described in this announcement. To the
fullest extent permitted by applicable law, Investec and its affiliates
accordingly disclaim all and any responsibility or liability whether arising
in tort, contract or otherwise (save as referred to above in this paragraph)
which they might otherwise have in respect of this announcement, or any
statement contained herein.

The information in this announcement has not been audited or otherwise
independently verified and no representation or warranty, express or implied,
is made as to, and no reliance should be placed on, the fairness, accuracy,
completeness or correctness of the information or opinions contained herein.
None of the Company or any of its affiliates, advisors or representatives
shall have any liability whatsoever (in negligence or otherwise) for any loss
whatsoever arising from any use of this announcement, or its contents, or
otherwise arising in connection with this announcement.

This announcement does not constitute or form part of any offer or invitation
to sell, or any solicitation of any offer to purchase any shares in the
Company, nor shall it or any part of it or the fact of its distribution form
the basis of, or be relied on in connection with, any contract or commitment
or investment decisions relating thereto, nor does it constitute a
recommendation regarding the shares of the Company.

Certain statements, statistics and projections in this announcement are or may
be forward looking. By their nature, forward‑looking statements involve a
number of risks, uncertainties or assumptions that may or may not occur and
actual results or events may differ materially from those expressed or implied
by the forward-looking statements. Accordingly, no assurance can be given that
any particular expectation will be met and reliance should not be placed on
any forward-looking statement. Accordingly, forward-looking statements
contained in this announcement regarding past trends or activities should not
be taken as representation that such trends or activities will continue in the
future. You should not place undue reliance on forward-looking statements,
which are based on the knowledge and information available only at the date of
this announcement's preparation.

The Company does not undertake any obligation to update or keep current the
information contained in this announcement, including any forward‑looking
statements, or to correct any inaccuracies which may become apparent and any
opinions expressed in it are subject to change without notice.

References in this announcement to other reports or materials, such as a
website address, have been provided to direct the reader to other sources of
information on AMS which may be of interest. Neither the content of AMS's
website nor any website accessible by hyperlinks from AMS's website nor any
additional materials contained or accessible thereon, are incorporated in, or
form part of, this announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPSEDFILEISEFL